Prescription drugs evaluation

It is important to note that separate branches of the TGA are responsible for prescription drug evaluation, OTC drug evaluation, regulation of therapeutic devices and compliance issues. There are approximately 350 staff involved in TGA operations. The offices and the laboratories are located at S5mionston in Canberra. Some evaluation work is contracted to external organisations, such as academic and teaching institutions. 

Approved Prescription Drug Products, with Therapeutic Equivalence Evaluations, Bureau of Dmgs, Pood and Dmg Administration, U.S. Dept, of Health and Human Services, Bethesda, Md., 1980. 

At each visit, evaluate the pharmacotherapy regimen for appropriate drug choice and dose, non-prescription drug use, adverse effects, and use of potentially hepatotoxic medications. 

Our empirical evaluation of competition between pharmaceuticals was based on information on prescription drug consumption by non-hospital patients in the National Health Service (NHS) in England in 19% and the Sistema Nacional de Salud or SNS (National Health System) in Spain in 1997. The authors wish to thank Statistics Division IE of the UK Department of Health and the Directorate-General of Pharmacy and Health Products of the Spanish Ministry of Health and Consumer Affairs for supplying us with these data. As can be seen from Table 4.1, public consumption of pharmaceuticals... 

Stuart, B. et al. (2000), Issues in prescription drug coverage, pricing, utilization and spending what we know and need to know , report prepared for US Department of Health and Human Services, Office of the Assistant Secretary for Policy and Evaluation, Office of Health Policy, Washington, DC, February, accessed at http //www.aspe.hhs.gov/health/reports/drugstudy/appa.htm. 

Fung, M., Thornton, A., Mybeck, K., Ksiao-Fhii, J., Hombuckle, K. and Muniz, E. (2001). Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets 1960 to 1999, Drug Information J. 35 293-317. 

Evaluation of characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets — 1960 to 1999. Drug Information Journal, 35, 293-317. 

The new structure of pharmaceutical research has not led to increased productivity or decreased costs, at least in terms of the number of new products introduced (Comanor, Chapter 3), although it may have influenced the therapeutic properties of the new drugs. The new structure for discovery and development of new pharmaceutical products has not improved efficiency if one measures R D output by the number of new molecular entities. However, prescription drugs are potentially important inputs in the production of good health (Sloan and Hsieh, Chapter 1 Cremeiux et al.. Chapter 12 Hsieh et al.. Chapter 13). Thus, the efficiency of pharmaceutical research is more appropriately evaluated in terms of its contribution to improvements... 

Congress passes the Prescription Drug User Fee Act, which requires the pharmaceutical industry to pay user fees to the FDA in return for faster approval time. With the funds, the FDA will hire new workers for the Center for Drug Evaluation and Research and the Center for Biologies Evaluation Research. 

A research and advocacy organization that evaluates alternative policies and programs, particularly those at the state level, in order to reduce prescription drug prices and increase access to medications. 

Meeting the FDA s key goal, to ensure the safety of prescription drugs, requires not only evaluation of risks before approval but also communicating safety information to the public. The first half of the 2001 document presented below explains how the agency works toward this goal. 

When an NDA comes in, the FDA has 60 days to decide whether to file it so that it can be reviewed. The FDA can refuse to file an application that is incomplete. For example, some required studies may be missing. In accordance with the Prescription Drug User Fee Act (PDUFA), the FDA s Center for Drug Evaluation and Research (CDER) expects to review and act on at least 90 percent of NDAs for standard drugs no later than 10 months after the applications are received. The review goal is six months for priority drugs. (See The Role of User Fees. )... 

Clinical trials have become the primary means to evaluate the safety of prescription drugs. They are required not only before approval but also after approval, when trials continue to identify any unrecognized problems. To encourage people to participate in these trials, the FDA describes what is involved and the benefits they provide in this document, updated on July 11, 2009. 

In his JAMA editorial, Coyle offered another reason for the increase in prescription drug use in that age group. He explained that reduced financing for state Medicaid programs have caused those programs to limit what they pay for the evaluation of behavioral disorders in children. 

---